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Abstract: In a randomized, double-blind, Phase III study, we compared pasireotide long-acting
release (pasireotide LAR) with octreotide long-acting repeatable (octreotide LAR) in managing
carcinoid symptoms refractory to first-generation somatostatin analogues. Adults with carcinoid
tumors of the digestive tract were randomly assigned (1:1) to receive pasireotide LAR (60 mg)
or octreotide LAR (40 mg) every 28 days. Primary outcome was symptom control based on
frequency of bowel movements and flushing episodes. Objective tumor response was a secondary outcome. Progression-free survival (PFS) was calculated in a post hoc analysis. Adverse
events were recorded. At the time of a planned interim analysis, the data monitoring committee
recommended halting the study because of a low predictive probability of showing superiority of pasireotide over octreotide for symptom control (n=43 pasireotide LAR, 20.9%; n=45
octreotide LAR, 26.7%; odds ratio, 0.73; 95% confidence interval [CI], 0.27–1.97; P=0.53).
Tumor control rate at month 6 was 62.7% with pasireotide and 46.2% with octreotide (odds
ratio, 1.96; 95% CI, 0.89–4.32; P=0.09). Median (95% CI) PFS was 11.8 months (11.0 – not
reached) with pasireotide versus 6.8 months (5.6 – not reached) with octreotide (hazard ratio,
0.46; 95% CI, 0.20–0.98; P=0.045). The most frequent drug-related adverse events (pasireotide
vs octreotide) included hyperglycemia (28.3% vs 5.3%), fatigue (11.3% vs 3.5%), and nausea
(9.4% vs 0%). We conclude that, among patients with carcinoid symptoms refractory to available
somatostatin analogues, similar proportions of patients receiving pasireotide LAR or octreotide
LAR achieved symptom control at month 6. Pasireotide LAR showed a trend toward higher
tumor control rate at month 6, although it was statistically not significant, and was associated
with a longer PFS than octreotide LAR.
Keywords: neuroendocrine tumors, carcinoid syndrome, somatostatin analogues, pasireotide,
symptom control, progression-free survival

Introduction
Neuroendocrine tumors (NET) are rare and heterogeneous neoplasms arising from the
diffuse neuroendocrine cell system.1 NET produce and secrete bioactive amines, peptides, and polypeptides.2 Excessive release of bioactive substances, primarily serotonin
and substance P, is associated with classic carcinoid syndrome in approximately 20%
of patients with metastatic NET arising from jejunum or ileum (functional NET).3,4
Clinical manifestations of carcinoid syndrome include episodic flushing, diarrhea, and
bronchoconstriction; 50%–66% of patients later develop valvular cardiac complications resulting from higher levels of 5-hydroxyindoleacetic acid and duration of the
elevated 5-hydroxyindoleacetic acid.3,5,6
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Somatostatin analogues (SSA) remain the gold standard
treatment for patients with functional NET.5,7 Octreotide
and lanreotide effectively reduce the frequency of diarrhea and flushing in 70%–90% of patients with carcinoid
symptoms.5,7–9 Loss of symptom response due to tachyphylaxis has been reported approximately 6–18 months after
initiation of treatment.10
Pasireotide (SOM230) is expected to have a distinct
pharmacodynamic profile given its broader specificity and
high affinity for somatostatin receptors 1–3 (sst 1–3) and
sst5 compared with octreotide and lanreotide, which have
greater specificity for sst2.11,12 In a recent Phase II study,
subcutaneous (SC) pasireotide effectively treated symptoms
of patients with metastatic functional carcinoid tumors
resistant to octreotide long-acting repeatable (octreotide
LAR) therapy.13
Our Phase III study compared the efficacy and safety
of pasireotide long-acting release (pasireotide LAR) with
those of octreotide LAR in controlling diarrhea and flushing
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in patients with metastatic NET whose disease-related
symptoms were inadequately controlled by the highest
recommended doses of first-generation SSA. A post hoc
progression-free survival (PFS) analysis was performed
following the results of objective tumor response.

Methods
Study design
This was a multicenter, randomized, blinded, efficacy and
safety, Phase III study of pasireotide LAR versus octreotide
LAR in patients with metastatic NET of the digestive
system who had inadequately controlled carcinoid symptoms. Planned enrollment was 216 patients (108 in each
arm; see the “Sample size and interim analysis” section in
supplementary materials, Table S1) from 47 centers in 15
countries (Argentina, Austria, Belgium, Brazil, Canada,
France, Germany, Italy, Norway, Poland, Singapore, Spain,
Sweden, UK, and USA) (Figure 1; ClinicalTrials.gov identifier, NCT00690430).
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Figure 1 Study design.
Notes: aDiarrhea and/or flushing while receiving maximum approved doses of a currently available SSA for $3 months; bstratification groups (according to inadequately
controlled baseline symptoms during a 2-week period [14 days] prior to randomization): D + F, mean daily bowel movements of four or more and total flushing episodes of
five or more; D, mean daily bowel movements of four or more and total flushing episodes of less than five; F, mean daily bowel movements of less than four and total flushing
episodes of 14 or more; cblinding was not maintained for patients who crossed over to pasireotide LAR. D, predominantly diarrhea group; D + F, diarrhea and flushing group;
F, predominantly flushing group.
Abbreviations: Octreotide LAR, octreotide long-acting repeatable; pasireotide LAR, pasireotide long-acting release; PS, performance status; RECIST, Response Evaluation
Criteria In Solid Tumors; SSA, somatostatin analogues.

5076

submit your manuscript | www.dovepress.com

Dovepress

Drug Design, Development and Therapy 2015:9

Dovepress

The study protocol was reviewed by an independent ethics
committee or institutional review board at each site and met
the principles of the Declaration of Helsinki. The study was
monitored by an independent data monitoring committee and
was overseen by a protocol steering committee. All patients
provided written informed consent before participation in
the study.

Patients
Adult patients (age $18 years) with carcinoid tumors of the
digestive tract were eligible for study enrollment if they had a
histopathologically confirmed metastatic tumor and one evaluable lesion as assessed according to Response Evaluation
Criteria In Solid Tumors (RECIST; version 1.0).14 For study
participation, disease progression prior to study entry was not
mandatory. Other key inclusion criteria included inadequately
controlled diarrhea and/or flushing (as defined under patient
screening and treatment) while receiving maximum approved
doses of the currently available SSA for 3 months prior to
study entry; Karnofsky performance status $60; and adequate
bone marrow, renal, and hepatic function. Previous SSA
doses to establish inadequate control during screening period
included octreotide LAR 30 mg every 28 days, octreotide SC
600 μg (total daily dose), lanreotide autogel 120 mg every
28 days, or lanreotide SR 30 mg every 14 days. Patients with
impaired fasting glucose or diabetes mellitus were eligible.
In such patients, HbA1c and fasting glucose were routinely
measured throughout the study period, additional monitoring was performed, and antidiabetic therapy was started as
clinically indicated per investigator’s discretion.
Patients were ineligible if they received an SSA at a higher
than approved dose (except a short-acting formulation) within
3 months before screening; were receiving radiolabeled SSA
therapy (within 3 months before recording baseline symptoms); received any cytotoxic chemotherapy or interferon
therapy (within 4 weeks); underwent major surgery (within
1 month before recording baseline symptoms) or surgical
therapy of locoregional metastases (within 3 months); underwent hepatic artery embolization, chemoembolization, or
radioembolization (yttrium 90 microspheres) within 6 months
(or 1 month if there were other disease sites) or cryoablation or radiofrequency ablation of hepatic metastases within
2 months before recording baseline symptoms; received prior
therapy with pasireotide; or had diabetes and poorly controlled
blood glucose levels (glycosylated hemoglobin .8%).

Patient screening and treatment
Inadequate control of carcinoid symptoms was defined as a
daily mean of four or more bowel movements over a 2-week
Drug Design, Development and Therapy 2015:9
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period and five or more flushing episodes during the same
period within the screening phase. Patients recorded symptoms during screening on a touch-tone telephone system.
After screening, eligibility confirmation, and a washout
period (see the “Washout period” section in supplementary
materials), patients were randomly assigned 1:1 to receive
blinded treatment with pasireotide LAR 60 mg or octreotide
LAR 40 mg. An interactive voice response system was used
for randomization. True double blinding was not feasible
due to the different appearances of the LAR formulations.
Blinding was achieved by an independent nurse who knew
the treatment assignment (see the “Treatment blinding” section in supplementary materials).
Treatments were administered via intragluteal depot
injections once every 28 days (±3 days) by an independent
study nurse. For patients who experienced breakthrough
symptoms after the first injection, SC rescue medication was
permitted (ie, pasireotide 600 μg bid SC for patients randomized to pasireotide LAR and octreotide 100 μg tid SC for
patients randomized to octreotide LAR). Dose reductions to
pasireotide LAR 40 mg and octreotide LAR 30 mg for safety
and tolerability were allowed (see the “Permitted study drug
adjustments” section in supplementary materials).
The treatment and evaluation periods for the core study
were 6 months. A blinded treatment extension of up to
2 years was available in all participating countries except
the UK. Patients not benefiting from octreotide by the end
of the 6-month core phase were allowed to switch to pasireotide LAR treatment on entry into the extension phase and
the blind was broken (see the “Extension study” section in
supplementary materials).

Assessments
Efficacy

The primary efficacy outcome was symptom control (diarrhea
and/or flushing) based on patient reports of daily frequency
of bowel movements and flushing episodes. A patient was
considered to be achieving symptom improvement according
to the following subgroup-specific criteria (over a 28-day
period comprising month 6): stratum D, less than four daily
mean bowel movements and $20% reduction in the daily
mean number of bowel movements from baseline; stratum
F, $30% reduction in the total number of flushing episodes
from baseline; and stratum D + F, less than four mean bowel
movements, and $20% reduction in the daily mean number
of bowel movements from baseline plus any reduction in the
total number of flushing episodes compared with baseline.
Secondary analyses included evaluating the frequency of
bowel movements alone and the number of flushing episodes
submit your manuscript | www.dovepress.com
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alone during month 6 (the last 28 days of treatment) relative
to the baseline assessment and the objective tumor response
rate (complete response or partial response) and tumor control
rate (complete response, partial response, or stable disease) at
month 6 using RECIST criteria (based on the tumor responses
assessed by the investigators). Tumors were measured using
computed tomography or magnetic resonance imaging at
baseline and every 3 months thereafter.

Safety
Safety assessments included monitoring and recording all
adverse events (AEs) based on the National Cancer Institute Common Terminology Criteria for Adverse Events,
version 3.0.15

Statistical analysis
The full analysis set consisted of all randomized patients.
Following the intent-to-treat principle, these patients
were analyzed according to the treatment assigned at randomization. Demographic and baseline characteristics as
well as tumor response were evaluated based on the full
analysis set.
The efficacy analyzable set consisted of the subset of
full analysis set patients randomized at least 6 months
before the futility data monitoring committee data cutoff. It was used to assess primary and secondary efficacy
outcomes, with the exception of tumor response. A twosided Cochran–Mantel–Haenszel test (adjusted for the
inadequately controlled symptom subgroups; significance
level, 0.05) compared proportions of patients experiencing
symptom improvement. Change from baseline in mean
daily bowel movements and flushing episodes at month 6
was compared using an analysis of covariance model.
A two-sided Fisher’s exact test compared objective tumor
response rate. Odds ratios (ORs) and corresponding 95%
confidence intervals (CIs) were calculated using logistic
regression.
The safety analysis set consisted of patients who received
at least one dose of study drug and had at least one postbaseline safety assessment, regardless of whether they
entered the extension phase.
The extension analysis set consisted of patients receiving at least one dose of study medication in the extension
phase and was used for safety analyses in the extension
phase. Patients in the extension analysis set were stratified
by the treatment received in the extension phase, as follows:
pasireotide LAR, patients continuing on pasireotide LAR
in the extension phase; octreotide LAR, patients continuing

5078
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on octreotide LAR in the extension phase; crossover to
pasireotide LAR, patients receiving octreotide LAR in the
core phase and pasireotide LAR in the extension phase.
Patients were excluded if no treatment information was
available on entry into the extension phase.
An exploratory analysis of PFS was performed to evaluate
the durability of the tumor response data. Distributions were
assessed by the Kaplan–Meier method and were compared
between treatment arms using a two-sided unstratified logrank test. Hazard ratio (HR) was estimated with unstratified
Cox regression.

Results
One hundred ten patients were enrolled between April 2008
and April 2012, before the study was halted following a
data monitoring committee recommendation due to a low
predictive probability of showing superiority of pasireotide
over octreotide for symptom control (Figure 2). Baseline
demographic and clinical characteristics of the patients in
the two treatment arms were similar (Table 1).

Efficacy
Similar proportions of patients receiving pasireotide LAR
(20.9%) or octreotide LAR (26.7%) achieved symptom
control at month 6 (OR, 0.73; 95% CI, 0.27–1.97; P=0.53)
(Table 2). At month 6, the magnitude of reduction in frequency of bowel movements and flushing episodes was
comparable between treatments (Table S2).

Objective tumor response
At month 6, a higher proportion of patients in the pasireotide
LAR arm (60.8%) than in the octreotide LAR arm (42.3%)
achieved stable disease, with a comparable objective
response rate between arms (2.0% in the pasireotide LAR
vs 3.8% in the octreotide LAR arm; OR, 0.50; 95% CI,
0.04–5.69; P=0.57). The tumor control rate at month 6 was
62.7% with pasireotide LAR and 46.2% with octreotide LAR
(OR, 1.96; 95% CI, 0.89–4.32; P=0.09). At 48 months, the
objective tumor response and disease control rates were
similar between treatment arms (Table S3).

Progression-free survival
In a post hoc analysis, the median PFS based on investigatorassessed tumor response was 11.8 months (95% CI, 11.0 –
not reached) in patients receiving pasireotide LAR versus
6.8 months (95% CI, 5.6 – not reached) in patients receiving
octreotide LAR (unstratified Cox regression model HR, 0.46;
95% CI, 0.20–0.98; P=0.045) (Figure 3).

Drug Design, Development and Therapy 2015:9
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110 patients enrolled

18 discontinued during 6-month core phaseb
8 had unsatisfactory therapeutic effect
5 had adverse events
3 withdrew consent
1 protocol deviation
1 drug no longer required

53 assigned to receive
pasireotide LAR
(full analysis set)a

57 assigned to receive
octreotide LAR
(full analysis set)a

35 completed
core phase

34 completed
core phase

21 entered
extension phase

20 entered
extension phase

18 discontinued during extension phase
10 had administrative problems
3 had unsatisfactory therapeutic effect
2 had adverse events
1 had abnormal laboratory values
1 had abnormal test procedure results
1 death

2 completed
extension phase

15 crossed over to
pasireotide

23 discontinued during 6-month core phaseb
10 had unsatisfactory therapeutic effect
6 had administrative problems
3 withdrew consent
2 deaths
1 abnormal laboratory value
1 had adverse event

6 continued
with octreotide

13 discontinued during extension phase
4 had unsatisfactory therapeutic effect
4 had administrative problemsc
2 had adverse events
2 withdrew consent
1 death

5 discontinued during extension phase
2 had administrative problemsc
1 had adverse event
1 death
1 had unsatisfactory therapeutic effect

2 completed
extension phase

1 completed
extension phase

Figure 2 Patient disposition.
Notes: Demographic and background characteristics. aTwo patients were incorrectly randomized; one patient randomized to the pasireotide LAR group actually received
six injections of octreotide LAR (this patient crossed over to pasireotide LAR in the extension phase and received eight injections of pasireotide LAR), and one patient
randomized to the octreotide LAR group actually received two injections of pasireotide LAR; bthree of four patients in the crossover group and one of two patients in the
octreotide LAR group discontinued due to early study termination; cpatients who completed month 6 and did not enter the extension are not counted as discontinuations.
Abbreviations: Octreotide LAR, octreotide long-acting repeatable; pasireotide LAR, pasireotide long-acting release.

Safety and tolerability
The most common drug-related AEs of any grade among
patients who received pasireotide LAR were hyperglycemia, fatigue, and nausea (Table 3). The rate of grade 3 or 4
hyperglycemia was higher with pasireotide LAR (9.4%) than
with octreotide LAR (1.8%).
AEs leading to treatment discontinuation were more
frequent with pasireotide LAR (17.0%) than with octreotide
LAR (7.0%). Two patients receiving pasireotide LAR
discontinued treatment because of grade 4 hyperglycemia,
which was manageable with antidiabetic medication. During
the core phase, AEs leading to study drug discontinuation
occurred in seven patients (13.2%) in the pasireotide LAR
arm and were considered study drug related in four patients
(7.5%): one patient each with diarrhea and flushing, diarrhea
and bradycardia, hyperglycemia, or liver enzyme elevation.
In the octreotide LAR arm, no events leading to study discontinuation were considered to be drug related. During the
extension phase, six patients discontinued the study drug due
to an AE: two patients in the pasireotide LAR arm, one patient
in the octreotide LAR arm, and three patients in the crossover
to pasireotide LAR arm. For two patients from the crossover

Drug Design, Development and Therapy 2015:9

arm, the drug-related AEs leading to study discontinuation
included orthostatic hypotension and dysesthesia and liver
enzyme elevation.
Serious AEs occurred with comparable frequency in the
pasireotide LAR (41.5%) and octreotide LAR (36.8%) arms,
although more serious AEs in the pasireotide LAR arm were
drug related (17% vs 3.5% with octreotide LAR). Five deaths
were reported: two in the octreotide LAR arm during the
core phase due to health deterioration or disease progression
and three during the extension phase due to disease progression (pasireotide LAR), hepatic failure (octreotide LAR),
and carcinoid tumor of the gastrointestinal tract (crossover
to pasireotide LAR). All deaths were attributed to disease
progression or underlying malignancy.

Discussion
SSA therapy remains the standard of care for treatment of
hormonal symptoms in functional NET. Many patients with
improved carcinoid symptoms experience recurrence and/
or worsening of symptoms despite continued treatment with
octreotide or lanreotide, and effective management of refractory carcinoid syndrome remains an unmet medical need.7,16
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Table 1 Demographic and baseline characteristics of the patients
Pasireotide
LAR n=53
Age (years), median (range)
61 (40–80)
Sex, n (%)
Male/female
29 (55)/24 (45)
Race, n (%)
Caucasian
49 (92)
Asian
1 (2)
Black
1 (2)
Other
2 (4)
Karnofsky performance status, n (%)
80–100
49 (93)
3 (6)
,80
Missing
1 (2)
Primary tumor site, n (%)
Small intestine
38 (72)
Colon
3 (6)
Liver
3 (6)
Pancreas
1 (2)
Lung
0
Stomach
0
Othera
8 (15)
Histologic grade of tumor, n (%)
Well differentiated
41 (77)
Moderately differentiated
2 (4)
Unknown
10 (19)
Tumor stage, n (%)
Stage I
0
Stage II
0
Stage III
2 (4)
Stage IV
46 (87)
Unknown/missing
0/5 (10)
Time since initial diagnosis (years), n (%)
6 (11)
0.5 to ,2
18 (34)
2 to ,5
11 (21)
5 to ,10
7 (13)
$10
Missing
11 (21)
Previous medications, n (%)
Chemotherapy
10 (19)
Immunotherapy
12 (23)
Targeted therapy
7 (13)
Other
14 (26)
Missing
26 (49)
Previous SSA use, n (%)b
Octreotide LAR
45 (85)
Octreotide SC
11 (21)
Lanreotide autogel
6 (11)
Lanreotide SR
3 (6)
No of patients with baseline
49
5-HIAA data
Elevated baseline 5-HIAA
44 (90)
(.ULN), n (%)
No of patients with
15
baseline CgA datac
Elevated baseline CgA
11 (73)
(.2× ULN), n (%)

Octreotide
LAR n=57
63 (28–86)
34 (60)/23 (40)
57 (100)
0
0
0
50 (88)
6 (11)
1 (2)
46 (81)
1 (2)
0
1 (2)
1 (2)
1 (2)
7 (12)
48 (84)
1 (2)
8 (14)
1 (2)
1 (2)
1 (2)
47 (83)
1 (2)/6 (11)
14 (25)
13 (23)
18 (32)
7 (12)
5 (9)
12 (21)
14 (25)
8 (14)
10 (18)
24 (42)
50 (88)
9 (16)
13 (23)
1 (2)
49
40 (82)
17
10 (59)

Notes: aOther sites included distal ilium, cecum, GI primary, recto-sigmoid,
unknown primary, mesentery, appendix, head of pancreas; bpatients might have
been taking more than 1 SSA prior to study entry; cbaseline CgA data were missing
for approximately 70% of patients as the CgA assessment was introduced with a
protocol amendment issued after 48 patients had been enrolled.
Abbreviations: CgA, chromogranin A; 5-HIAA, 5-hydroxyindoleacetic acid; GI,
gastrointestinal; octreotide LAR, octreotide long-acting repeatable; pasireotide
LAR, pasireotide long-acting release; SC, subcutaneous; SR, sustained release; SSA,
somatostatin analogues; ULN, upper limit of normal.
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Although options such as combining interferon-alpha with
SSA or locoregional treatment (such as hepatic transcatheter
arterial embolization) could be considered in refractory
patients, the lack of data from well-controlled studies and
poor tolerance due to AEs with such therapies substantiate
the need for new agents. Pasireotide LAR was as effective as high-dose octreotide LAR in controlling symptoms
refractory to the highest recommended doses of firstgeneration SSA.
It was anticipated that pasireotide LAR would have greater
efficacy than octreotide LAR due to its broader receptorbinding profile. During the planned interim futility analysis,
however, the study showed similar efficacy for symptom control in an SSA-refractory population despite ~40% of patients
in each treatment arm discontinuing the study. The higher
discontinuation rates due to unsatisfactory therapeutic effect,
15% in the pasireotide LAR arm and 17% in the octreotide
LAR arm, is not unexpected considering that the study population were refractory to SSA therapy for symptom control
at study entry. In addition, imbalances between treatment
arms in baseline demographic characteristics (particularly
proportions of patients with a shorter period since initial
diagnosis, Karnofsky score, and heterogeneity of primary
tumor sites) might have confounded results.
Earlier, in an open-label, multicenter, Phase II study,
Kvols et al13 evaluated pasireotide SC (600–900 µg bid)
in 45 patients with metastatic NET resistant to octreotide
LAR. They showed that pasireotide effectively controlled
carcinoid syndrome symptoms in 27% of patients (symptom
control for diarrhea and flushing over any consecutive 15-day
period at a fixed dose of pasireotide, efficacy population).13
Consistent with these findings, we found that after 6 month’s
treatment, pasireotide LAR controlled symptoms in 21% of
patients refractory to octreotide or lanreotide. Collectively,
the results strongly support pasireotide LAR as an effective
medical therapy for symptom control in patients with carcinoid syndrome inadequately controlled by currently available
SSA. The applicability of the findings to SSA treatment-naive
patients merits investigation.
SSA have demonstrated antitumor activity in addition to
their effects on symptom control in patients with functional
NET. Octreotide is the first SSA shown to have antitumor
efficacy in a Phase III randomized controlled trial. In the
PROMID (Placebo-controlled, double-blind, prospective,
Randomized study on the effect of Octreotide LAR in the
control of tumor growth in patients with metastatic neuroendocrine MIDgut tumors) study, octreotide LAR significantly
prolonged median time to tumor progression in patients with
newly diagnosed advanced metastatic midgut NET with or
Drug Design, Development and Therapy 2015:9
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Table 2 Symptom response: efficacy analyzable seta
Stratum

Pasireotide LAR n/N (%)
[95% exact CI]

Octreotide LAR n/N (%)
[95% exact CI]

Between treatment
OR [95% CI]

Diarrhea and flushing
Predominantly diarrhea
Predominantly flushing
Overall

5/37 (13.5) [4.5–28.8]
2/2 (100) [15.8–100]
2/4 (50.0) [6.8–93.2]
9/43 (20.9) [10.0–36.0]

11/39 (28.2) [15.0–44.9]
1/5 (20.0) [0.5–71.6]
0/1 (0) [0.0–97.5]
12/45 (26.7) [14.6–41.9]

0.40 [0.12–1.29]

0.73 [0.27–1.97]
P=0.53

Note: aThe efficacy analyzable set consisted of the subset of the full analysis set who were randomized at least 6 months before the futility data monitoring committee data
cutoff.
Abbreviations: CI, confidence interval; n/N, number of responders/number of patients analyzed; octreotide LAR, octreotide long-acting repeatable; OR, odds ratio;
pasireotide LAR, pasireotide long-acting release.

without secretory symptoms (14.3 months vs 6.0 months
with placebo; HR, 0.34; 95% CI, 0.20–0.59; P=0.000072).17
In the same study, 66.7% of patients receiving octreotide
LAR experienced stable disease after 6 months (vs 37.2%
of those from the placebo arm). Recently, the CLARINET
study showed that lanreotide improved PFS in patients with
stable disease gastroenteropancreatic NET versus placebo
(lanreotide, PFS not reached; placebo, PFS 18 months; HR,
0.47; 95% CI, 0.30–0.73; P=0.0002).18
This study was designed to evaluate efficacy of pasireotide
for symptom control, and therefore documentation of disease
progression prior to study entry was not required. An improved,
though not statistically significant, tumor control rate at
6 months for patients receiving pasireotide LAR in our study
(62.7% vs 46.2% in patients receiving octreotide LAR; OR,
1.96; 95% CI, 0.89–4.32; P=0.09) drove an exploratory PFS
analysis. In the post hoc analysis, pasireotide LAR prolonged

median PFS by 5 months (11.8 months vs 6.8 months with
octreotide LAR), corresponding to a 54% reduction in estimated risk for disease progression or death (HR, 0.46; 95% CI,
0.20–0.98; P=0.045). This effect of pasireotide LAR on PFS is
very encouraging given the refractory population. Data from a
recent open-label, Phase II study of pasireotide LAR have also
shown promising antitumor efficacy with PFS of 12.2 months
(95% CI, 7.7–17.5) in patients with metastatic NET without
prior systemic therapy, including octreotide or lanreotide.19
The antitumor activity of pasireotide LAR warrants further
exploration in a larger study with PFS and additional tumor
control metrics as predefined end points.
The tumor control rate at 6 months observed in the
octreotide LAR arm of our study was 46.2%, whereas that
observed in the PROMID trial was 66.7%.17 Our study is not
easily comparable with the PROMID study, in which most
patients were treatment naive, whereas all patients in our

Total events =38
Pasireotide LAR (n/N=18/52)
Octreotide LAR (n/N=20/56)
Censored

1.0

Survival probability

0.8

Kaplan–Meier median PFS
Pasireotide LAR: 11.8 months, 95% Cl (11.0 – not reached)
Octreotide LAR: 6.8 months, 95% Cl (5.6 – not reached)
Hazard ratio =0.46, 95% Cl (0.20–0.98)
P=0.045 (log-rank test)
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Figure 3 Kaplan–Meier plot of progression-free survival based on investigator-assessed tumor response.
Abbreviations: CI, confidence interval; n/N, number of responders/number of patients analyzed; octreotide LAR, octreotide long-acting repeatable; pasireotide LAR,
pasireotide long-acting release; PFS, progression-free survival.
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Table 3 Drug-related adverse events reported in at least 5% of patients
Preferred term, n (%)

Hyperglycemia
Fatigue
Nausea
Flatulence
Diabetes mellitus
Diarrhea
Blood glucose increased
Alanine aminotransferase increased
Aspartate aminotransferase increased
Rash
Abdominal pain
Asthenia
Cholelithiasis
Pain in extremity
Injection site pain
Albumin urine present
Glycosylated hemoglobin increased
Hypokalemia
Dysesthesia
Loss of consciousness
Alopecia
Hyperhidrosis
Orthostatic hypotension

Pasireotide LAR
n=53

Octreotide LAR
n=42

Crossover to
pasireotide LAR n=15a

All
grades

Grade 3
or 4

All
grades

Grade 3
or 4

All
grades

Grade 3
or 4

15 (28.3)
6 (11.3)
5 (9.4)
4 (7.5)
4 (7.5)
3 (5.7)
3 (5.7)
2 (3.8)
2 (3.8)
2 (3.8)
1 (1.9)
1 (1.9)
1 (1.9)
1 (1.9)
0
0
0
0
0
0
0
0
0

5 (9.4)
0
0
0
1 (1.9)
2 (3.8)
0
2 (3.8)
2 (3.8)
0
1 (1.9)
0
0
0
0
0
0
0
0
0
0
0
0

3 (5.3)
2 (3.5)
0
0
0
1 (1.8)
0
1 (1.8)
1 (1.8)
0
0
2 (3.5)
3 (5.3)
0
1 (1.8)
0
0
0
0
0
0
0
0

1 (1.8)
1 (1.8)
0
0
0
0
0
0
0
0
0
0
1 (1.8)
0
0
0
0
0
0
0
0
0
0

2 (13.3)
1 (6.7)
2 (13.3)
0
1 (6.7)
0
0
1 (6.7)
1 (6.7)
1 (6.7)
1 (6.7)
1 (6.7)
0
1 (6.7)
1 (6.7)
1 (6.7)
1 (6.7)
1 (6.7)
1 (6.7)
1 (6.7)
1 (6.7)
1 (6.7)
1 (6.7)

0
0
0
0
0
0
0
1 (6.7)
0
0
0
0
0
0
0
0
0
0
0
1 (6.7)
0
0
1 (6.7)

Note: aAny adverse event occurring before crossover is presented in the octreotide LAR arm.
Abbreviations: Octreotide LAR, octreotide long-acting repeatable; pasireotide LAR, pasireotide long-acting release.

study were symptomatic while being treated with the highest
recommended doses of available SSA.
The safety profiles of pasireotide and octreotide were
consistent with the known safety profiles of both agents.
Although the incidence of hyperglycemia was higher in the
pasireotide LAR arm, it was manageable. One patient discontinued due to hyperglycemia suspected to be related to the
study drug. The increased incidence of hyperglycemia among
patients receiving pasireotide has been reported.13,19 No cases
of ketosis or ketoacidosis were observed in this study.
Studies of pasireotide LAR in patients with NET are
ongoing. The Phase I COOPERATE-1 study has been
extended to evaluate the long-term safety and tolerability of
pasireotide LAR combined with everolimus (NCT01590199).
The randomized, open-label, Phase II COOPERATE-2 study
will investigate the efficacy of pasireotide LAR plus everolimus in patients with advanced progressive pancreatic NET
(NCT01374451).

Conclusion
In conclusion, our findings show that pasireotide LAR and
high-dose octreotide LAR have similar efficacy for symptom control in patients with functional NET and symptoms
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inadequately controlled with the highest recommended doses
of available SSA. At month 6, a trend toward higher tumor
control rate was observed with pasireotide LAR, although it
was statistically not significant. Pasireotide LAR was associated with a longer PFS compared with octreotide LAR.
Safety findings were consistent with known AE profiles for
both drugs. These results support further investigation of the
antitumor activity of pasireotide LAR in adequately powered
prospective Phase III studies and establish its role in tumor
control for patients with NET.
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Supplementary materials
Sample size and interim analysis
Among patients with inadequately controlled symptoms
in both diarrhea and flushing (D + F), the response rate for
octreotide long-acting repeatable (LAR; 40 mg) treatment
is estimated by medical experts to be ~20%. Given that the
primary analysis is based on the full analysis set according to
intent-to-treat principle, the treatment effect may be diluted
due to early dropouts since early dropouts are considered
treatment failures. With an estimated 20% dropout rate, the
response rate based on full analysis set was expected to be
32% for pasireotide long-acting release (LAR) versus 16%
for octreotide LAR. The primary efficacy end point was to
be analyzed using a two-sided Cochran–Mantel–Haenszel
test adjusting for the inadequately controlled symptom
subgroups. This allows for detection of an odds ratio of 2.5.
The estimated patient population from each subgroup is
listed in Table S1.
A 20% difference was considered clinically meaningful
to demonstrate the superiority of pasireotide over octreotide
among this group of patients. With one interim analysis using
15% predictive power boundary, when 40% of patients complete the study, a sample size of 216 patients (108 patients
per treatment arm) will be able to detect a common odds ratio
of 2.5 between pasireotide LAR and octreotide LAR with
77% power, adjusting for the three inadequately controlled
symptom groups.

Interim analysis
A futility analysis was planned to be performed when 40% of
patients (approximately 86) completed the month 6 assessment. This included all patients who were randomized at
least 6 months before the data cutoff date for the futility
analysis. The primary intent of this futility analysis was to
assess the risk–benefit ratio and to assess whether the study
should be stopped in case futility was demonstrated based
on the primary end point: proportion of patients achieving
response at month 6. Analysis results were to be reviewed
Table S1 Estimated patient population by inadequately controlled
symptom subgroup
Subgroup Expected patient Response rate, %
distribution, %
Pasireotide LAR Octreotide LAR
D+F
D
F

25
50
25

32
32
32

16
16
16

Notes: D, predominantly diarrhea group; D + F, diarrhea and flushing group; F,
predominantly flushing group; octreotide LAR, octreotide long-acting repeatable;
pasireotide LAR, pasireotide long-acting release.
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Table S2 Change in mean daily bowel movements and
number of flushing episodes at month 6 from baseline: efficacy
analyzable set
Pasireotide
LAR n=43

Octreotide
LAR n=45

Between treatment
LSM (95% CI)

Mean daily bowel movements (mean ± standard deviation)
na
26
32
Baseline
4.9±1.4
6.7±3.3
Month 6
3.5±1.4
4.0±2.3
% change
-25.1±24.0
-36.5±29.1
6.9 (-8.0 to 21.9)
Number of flushing episodes per 14-day interval
(mean ± standard deviation)
na
28
29
Baseline
74.0±50.3
76.6±64.5
Month 6
44.8±43.7
31.1±37.2
% change
-42.1±38.8
-49.4±36.7
4.5 (-15.9 to 24.8)
Note: aNumber of patients analyzed.
Abbreviations: CI, confidence interval; LSM, least-squares mean; octreotide LAR,
octreotide long-acting repeatable; pasireotide LAR, pasireotide long-acting release.

by the data monitoring committee, which was then to recommend whether the study should continue. A futility boundary
defined in terms of predictive power (PP) was used for the
futility analysis. PP was the probability of rejecting the null
hypothesis at the final analysis given the data observed at
the interim. The response rate affects the PP only through its
prior distribution. For calculating PP, it was assumed that the
response rate came from a noninformative prior (ie, beta (1, 1)
distribution), which is equivalent to a prior sample size of 1.
The futility analysis had the following characteristics:
Table S3 Best overall tumor response rate by investigator
assessment: full analysis set

Number of patients analyzed
Tumor response rate, n (%)
CR
PR
SD
PD
UNK
Response analysis, n (%)
ORR (CR + PR)
[95% CI]

Disease control rate (CR +
PR + SD) [95% CI]

Pasireotide
LAR n=53

Octreotide
LAR n=57

51

52

0
1 (2.0)
36 (70.6)
5 (9.8)
9 (17.6)

0
1 (1.9)
38 (73.1)
6 (11.5)
7 (13.5)

1 (2.0)
1 (1.9)
[0.0–10.4]
[0.0–10.3]
OR, 1.02; 95% CI, 0.06–16.76
P=0.99
37 (72.5)
39 (75.0)
[58.3–84.1]
[61.1–86.0]
OR, 0.88; 95% CI, 0.37–2.12
P=0.78

Abbreviations: CI, confidence interval; CR, complete response; octreotide LAR,
octreotide long-acting repeatable; OR, odds ratio; ORR, objective response rate;
pasireotide LAR, pasireotide long-acting release; PD, progressive disease; PR, partial
response; SD, stable disease; UNK, unknown.
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• It was planned to be performed when 40% of patients
(~86) had had the chance to complete the month 6
assessment.
• It was nonbinding (ie, the P-value of rejecting the null
hypothesis was not impacted by the futility analysis and
remained at two-sided 0.05).
• Predictive power boundary of 15% was the futility
boundary.
At interim, if PP was #15%, then the trial could be discontinued due to lack of efficacy.

Washout period
For patients on a long-acting somatostatin analogues (SSA),
symptom recordings started immediately after patients
received the last dose of SSA and continued for 4 weeks
(28 days). The last 2-week period (days 15–28) was used to
assess the frequency of diarrhea and flushing events at baseline. Use of octreotide subcutaneous (SC) or a short-acting
antidiarrheal agent was permitted during the first 2 weeks
(ie, before baseline assessment) as needed for symptom
control. However, no additional treatment was allowed during the last 2-week period (ie, during baseline assessment,
days 15–28). In addition, patients were to observe an 8-hour
interval between the last octreotide SC dose or a short-acting
antidiarrheal agent before the start of the baseline assessment
period on day 15.
For the patients who were receiving a short-acting SSA
before study entry, baseline assessment started immediately
after their enrollment and continued for 2 weeks (14 days).
These patients continued their prior treatment while baseline
assessments were being recorded. No other medication to
control carcinoid symptoms was permitted during baseline
assessment for these patients.

Treatment blinding
Due to the different appearances of the LAR formulations, a
true double-blind treatment was not feasible. Blinding was
achieved by having an independent study nurse/coordinator
(to whom the treatment assignment was known) administer
the LAR injections. The patient, investigator, and sponsor
were blinded to treatment assignment. The independent
study nurse/coordinator was required to keep the treatment
information confidential and was instructed not to discuss
or release information on treatment identities to the patient,
the investigator, the sponsor’s clinical monitor, or other
unauthorized personnel. Before study drug administration,
the independent nurse/coordinator had to document the date
and time of administration, detach the outer part of the label
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from the packaging, record the patient number on the label,
and affix it to the source document (drug label form) containing that patient’s unique patient number. This document was
kept strictly concealed from the patient, the investigator, and
the sponsor’s clinical monitor. Immediately after study drug
administration, the nurse/study coordinator was instructed
to remove vials, ampules, reconstitution vials, and the outer
packing and to lock them in a location inaccessible to others.
In addition, the persons performing the assessments and the
data analysts were blinded to the identity of the treatment
from the time of randomization until the study had been
completed, using the following methods: randomization
data were kept strictly confidential until the time of unblinding and were not accessible by anyone else involved in the
treatment; the identity of the LAR intramuscular depot
treatments was concealed by the independent study nurse,
who prepared and administered the injections. Investigators
who wished to continue a patient in the extension-treatment
period remained blinded if the decision was for the patient to
continue the same treatment as in the core phase of the study.
Unblinding was allowed after the patient completed 2 years
in the extension after all end-of-study assessments had been
completed and recorded; however, sponsor personnel and
groups performing central assessments remained blinded
to treatment until the database was locked. The identity of
the SC treatments was concealed by the use of study drugs
that were identical in packaging, labeling and schedule of
administration, appearance, and odor.

Permitted study drug adjustments
After the first injection, patients who experienced breakthrough symptoms were permitted rescue medications as
needed (ie, pasireotide 600 μg bid SC for patients randomized
to pasireotide LAR and octreotide 100 μg tid SC for patients
randomized to octreotide LAR). SC injections were interrupted if they led to tolerability issues but could be resumed
if needed once the tolerability issue resolved. The pasireotide
and octreotide rescue medications were supplied in doubleblind packaging and were self-administered by patients.
Dose reductions to pasireotide LAR 40 mg and octreotide
LAR 30 mg were permitted to improve tolerability. Patients
requiring dose reductions returned to the higher dose once
the tolerability issue resolved.

Extension study
The treatment and evaluation period for core study was
6 months. Patients benefiting from either treatment per
investigator assessment and not experiencing unacceptable
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toxicity were permitted to continue the same treatment and
dose for up to 2 years in the extension phase in a blinded
manner. Patients not benefiting from pasireotide during the
core phase were discontinued, and those not benefiting from
octreotide by the end of the core phase were switched to
pasireotide LAR treatment on entry into the extension phase

and the blind was broken. Patients in the extension phase
recorded their symptoms daily in a paper diary. The treatment
extension stage was stopped once the patient had achieved
2 years of the treatment extension or when pasireotide was
commercially available or the development program was
discontinued, whichever came first.
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